United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride injection, usp is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine hcl is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

United States - English - NLM (National Library of Medicine)

nucare pharamceuticals,inc. - clotrimazole (unii: g07gz97h65) (clotrimazole - unii:g07gz97h65), betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - clotrimazole 10 mg in 1 g - clotrimazole and betamethasone dipropionate cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to epidermophyton floccosum, trichophyton mentagrophytes, and trichophyton rubrum in patients 17 years and older. none. teratogenic effects pregnancy category c there are no adequate and well-controlled studies with clotrimazole and betamethasone dipropionate cream in pregnant women. therefore, clotrimazole and betamethasone dipropionate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. there have been no teratogenic studies performed in animals or humans with the combination of clotrimazole and betamethasone dipropionate. corticosteroids are generally teratogenic in laboratory animals when administered at relatively low dosage levels. studies in pregnant rats with intravaginal doses up to 100 mg/kg (15 times the maximum

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - allopurinol (unii: 63cz7gjn5i) (allopurinol - unii:63cz7gjn5i) - allopurinol 100 mg - this is not an innocuous drug. it is not recommended for the treatment of asymptomatic hyperuricemia. allopurinol reduces serum and urinary uric acid concentrations. its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see clinical pharmacology, contraindications, warnings, and precautions). allopurinol is indicated in: - the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). - the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. treatment with allopurinol should be discontinued when the potential for over production of uric acid is no longer present. the man

United States - English - NLM (National Library of Medicine)

hospira, inc. - tromethamine (unii: 023c2whx2v) (tromethamine - unii:023c2whx2v) - tromethamine 3.6 g in 100 ml - tham solution (tromethamine injection) is indicated for the prevention and correction of metabolic acidosis. in the following conditions it may help to sustain vital functions and thus provide time for treatment of the primary disease: tham solution (tromethamine injection) is contraindicated in uremia and anuria. in neonates it is also contraindicated in chronic respiratory acidosis and salicylate intoxication.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - docusate sodium (unii: f05q2t2ja0) (docusate - unii:m7p27195ag) - stool softener laxative - relieves occasional constipation (irregularity) - generally produces bowel movement in 12 to 72 hours

United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.   limitations of use: • use only if a clear diagnosis of migraine headache has been established. if a patient has no response to the first migraine attack treated with sumatriptan, reconsider the diagnosis of migraine before sumatriptan tablets are administered to treat any subsequent attacks. • sumatriptan tablets are not indicated for the prevention of migraine attacks. • safety and effectiveness of sumatriptan tablets have not been established for cluster headache. sumatriptan tablets are contraindicated in patients with: • ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal’s angina [see warnings and precautions (5.1 )] • wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precautions (5.2 )]  • history of

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - - sedative - anticonvulsant – for the treatment of generalized and partial seizures. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. controlled substance – phenobarbital is a schedule iv drug. dependence – barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the same level of intox

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - arctostaphylos uva-ursi leaf (unii: 3m5v3d1x36) (arctostaphylos uva-ursi leaf - unii:3m5v3d1x36), berberis vulgaris root bark (unii: 1th8q20j0u) (berberis vulgaris root bark - unii:1th8q20j0u), chimaphila umbellata (unii: wck21a9w9j) (chimaphila umbellata - unii:wck21a9w9j), equisetum hyemale (unii: 59677rxh25) (equisetum hyemale - unii:59677rxh25), hydrangea arborescens root (unii: sfk828q2de) (hydrangea arborescens root - unii:sfk828q2de), petroselinum crispum (unii: 1wza4y92ex) (petroselinum crispu - for the temporary relief of symptoms related to bladder and kidney complications, such as incontinence and inflammation.** ** these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.  for the temporary relief of symptoms related to bladder and kidney complications, such as incontinence and inflammation.** ** these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) -

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - atorvastatin calcium (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - atorvastatin 40 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 prevention of cardiovascular disease in adults in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low hdl-c, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: reduce the risk of myocardial infarction reduce the risk of stroke reduce the risk for revascularization procedures and angina in adult patients with type 2 diabetes